Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1163130 Target Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase · SINGLE PROTEIN · Trypanosoma cruzi

21Compounds
7Assays
4Approved Drugs
31.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q27793. Use UniProt Q27793 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q27793 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL1163130, mapped to UniProt Q27793. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional dihydrofolate reductase-thymidylate synthase
SINGLE PROTEIN · Trypanosoma cruzi
As of 2026-09-14
ChEMBL target ID
CHEMBL1163130
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q27793
Bifunctional dihydrofolate reductase-thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional dihydrofolate reductase-thymidylate synthase is the right protein anchor across sources, using UniProt Q27793 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional dihydrofolate reductase-thymidylate synthase
UniProt AccessionQ27793
Component TypeProtein
Sequence Length521 aa

Bifunctional dihydrofolate reductase-thymidylate synthase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt Q27793. Sequence length is 521 aa.

Mapped IDQ27793
Review nameBifunctional dihydrofolate reductase-thymidylate synthase
OrganismTrypanosoma cruzi
Clinical Profile

Clinical Phase Distribution

4
Approved
Assay Mix

Activity Type Distribution

IC5019.0
KI12.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL34259 8.96 IC50 1.1 Approved
CHEMBL1165388 8.89 Ki 1.3 Preclinical
CHEMBL1163286 8.8 Ki 1.6 Preclinical
CHEMBL1165305 8.8 Ki 1.6 Preclinical
CHEMBL1165306 8.48 Ki 3.3 Preclinical
CHEMBL1164279 8.44 Ki 3.6 Preclinical
CHEMBL5914970 8.25 IC50 5.62 Preclinical
CHEMBL5941843 8.25 IC50 5.62 Preclinical
CHEMBL5838395 8.21 IC50 6.17 Preclinical
CHEMBL119 8.18 Ki 6.6 Approved
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
2
6.0
1
6.5
4
7.0
10
7.5
10
8.0
4
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRIMETREXATE
CHEMBL119
Approved 1993
METHOTREXATE
CHEMBL34259
Approved 1953
PYRIMETHAMINE
CHEMBL36
Approved 1953
Assay Landscape

Assay Landscape

7
Total Assays
21
Tested Compounds
1
Assay Types
Binding — 7 assays, 21 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 7 21 7.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine